Emmanuel Hanon – Senior VP, Vaccines R&D, GSK
In an exclusive interview, GSK’s Senior VP for Vaccines R&D Dr Emmanuel Hanon discusses how the sharing of GSK’s adjuvant technology with a wealth of scientific institutions and companies globally…
Address: Haasrode Researchpark 1724
Romeinse straat 12 bus 2
3001 Leuven
Belgium
Tel: +32 (0) 16 39 60 60
TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with a commercial product and a strong clinical stage pipeline of adult stem cell programs. The company’s lead product, ChondroCelect®, for cartilage repair in the knee, is the only approved cell-based product in Europe, and is currently being launched across Europe. TiGenix’s adipose derived allogeneic stem cell platform has been extensively validated. The company has initiated a Phase III clinical trial to treat complex perianal fistulas in patients with Crohn’s disease, has a Phase IIa trial in rheumatoid arthritis ongoing, and has successfully concluded a Phase I trial to investigate intra-lymphatic administration in autoimmune disorders. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands).
ChondroCelect® for cartilage regeneration in the knee is an implantation suspension of characterised viable autologous (from the patient her- or himself) cartilage cells. The product is administered to patients in an autologous chondrocyte implantation procedure known as Characterised Chondrocyte Implantation (CCI), a surgical procedure to treat cartilage defects, in conjunction with debridement (preparation of the defect bed), a physical seal of the lesion (placement of a biological membrane, preferentially a collagen membrane) and rehabilitation.
ChondroCelect is the first cell-based product to successfully complete the entire development track from research to clinical development to approval by the European Medicines Agency as an Advanced Medicinal Therapy Product in October, 2009. ChondroCelect is commercially available in Belgium, the Netherlands, Luxemburg, Germany, the United Kingdom, Finland, and Spain.
Moreover, TiGenix uniquely combines early stage revenues from its ChondroCelect sales with the mid- to long-term commercial potential from its expanded adipose stem cell pipeline.
In an exclusive interview, GSK’s Senior VP for Vaccines R&D Dr Emmanuel Hanon discusses how the sharing of GSK’s adjuvant technology with a wealth of scientific institutions and companies globally…
Veronique Walsh, General Manager of Bristol Myers Squibb (BMS) – Benelux, explains her ambition to build a new company culture following the acquisition of Celgene. Walsh also lays bare the…
Stakeholders from the Belgian parallel trade industry outline how their activities are helping to solve medicine shortages in Europe and ensure patients have access to the medicines they need. They…
Geert Van Hoof, founding general manager of Chiesi Belgium, shares the exciting milestones of the company’s first decade in Belgium, including their stunning year-on-year double-digit growth, their market leadership in…
Tanguy Schmitz, president of the Belgian Association of Parallel Importers & Exporters (BAPIE) outlines some of the recent work that the parallel distribution industry to ensure the supply of medicines…
Four Belgium country managers for some of the world’s largest pharma companies give their words of wisdom for women starting out in the industry. “Focus on your strengths” Sonja…
Filip Van de Vliet and Gérard Lefèbvre of Alter Pharma Group discuss the value that parallel importing is bringing to Belgian patients and the evolving relationship between parallel importers and…
Marijke Eyssen of the Belgian Health Care Knowledge Centre (KCE) introduces the institution’s mission, core values, how it chooses areas of research, and the crucial work the KCE does in…
Janssen in Belgium was founded in 1953 by Dr Paul Janssen, with only one thing in mind: saving people’s lives through the development of better medicines. In 1961, the company…
Professor Sylvie Rottey, president of the Belgian Society of Medical Oncology (BSMO) outlines the state of cancer care in Belgium, the country’s positioning in clinical trials for medical oncology, and…
Erik Present is president of Healixia, a newly formed association for medical professionals in Belgium. Present introduces the mission and purpose of Healixia, the work it is currently undertaking in…
Sabena Solomon, general manager of GSK Benelux, speaks about her first impressions of the Belgium market, having come from GSK Finland, and her initial priorities for leading the affiliate. Solomon…
See our Cookie Privacy Policy Here
